George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10,700.00
Bid: 10,700.00
Ask: 10,702.00
Change: -42.00 (-0.39%)
Spread: 2.00 (0.019%)
Open: 10,756.00
High: 10,780.00
Low: 10,700.00
Prev. Close: 10,742.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Results of GSK and AstraZeneca trials may widen ovarian cancer drug use

Sat, 28th Sep 2019 17:46

* Drug candidates are in class known as PARP inhibitors

* Companies to discuss results with healthcare regulators
(Adds details on patient subgroup, sales estimates)

By Ludwig Burger

BARCELONA, Sept 28 (Reuters) - GlaxoSmithKline and
AstraZeneca both reported trial results that will likely
make their competing drugs available to a wider group of ovarian
cancer patients, possibly helping GSK catch its rival in a
highly contested drug class.

The two said separately on Saturday their drug candidates -
in a class known as PARP inhibitors - staved off the return of
metastasized ovarian cancer in women who had responded to
initial standard treatment, reducing the risk of a relapse.

AstraZeneca and its U.S. development partner Merck & Co
said their Lynparza drug cut the risk of the cancer
progressing again by 41%. The figure was 38% for GSK's drug.

The companies said they would discuss the results with
healthcare regulators with a view to a wider label.

Analysts have seen AstraZeneca and Merck's Lynparza in the
lead with an average sales estimate of $3.1 billion for 2023.
GSK's Zejula is seen achieving about 870 million pounds ($1.1
billion) in revenue that year.

But different trial settings will make it difficult to
predict how physicians will weigh up the two drugs.

While the Lynparza trial worked on the assumption that
patients get an initial treatment of chemotherapy plus Roche's
Avastin, the trial with GSK's Zejula included only
patients who had initially gone through chemotherapy only.

AstraZeneca argues that more than half of advanced ovarian
cancer patients in developed countries already get Avastin, with
the rate increasing, while GSK says concerns about side effects
may speak against the Roche drug.

Both companies, which are competing to burnish their
oncology credentials, showed that not just the small group of
women with mutated BRCA genes can benefit as the results also
covered the full variety of ovarian cancer.

Many cancer cells have a limited ability to make DNA repairs
during cell division, as healthy cells would. This feature makes
tumours genetically volatile and helps them develop resistance
to treatment over time.

GENETIC MUTATIONS

Drugmakers try to use that to their advantage with PARP
inhibitors, which block what is left of the DNA repair mechanism
so cancer cells fail to replicate. Mutated BRCA genes make the
DNA repair particularly weak, which is why PARP inhibitors have
been approved already for that subgroup.

Both trials showed benefit in using Zejula or Lynparza also
in tumours with a wider range of genetic mutations that hamper
DNA repairs, grouped together under the term homologous
recombination deficiency (HRD).

But in a patient subgroup with tumours where the DNA repair
was still intact, GSK appears to make headway over its rivals.

That group, which according to GSK accounts for about half
of ovarian cancer cases, showed a reduction in the cancer
relapse risk by 32%, when given Zejula.

In the Lynparza trial, however, there was no meaningful
benefit in that cohort. But reliable tests on HRD have yet to
become widely available.

"We know now we can use PARP inhibitors in the first-line
setting beyond women with BRCA mutations," said Susana Banerjee,
an oncologist at the Royal Marsden NHS Foundation Trust in
London, who discussed the results at an ESMO press conference.

"I think the key question really is, what about patients
that don't have HR deficiency?" Banerjee added.

Zejula was the lead compound of U.S. cancer specialist
Tesaro, which GSK acquired for $5.1 billion in December.

Other approved PARP inhibitors, Pfizer's Talzenna and Clovis
Oncology's Rubraca, are seen as further behind in terms
of future revenue prospects. Abbvie is testing an
experimental compound called veliparib.

($1 = 0.8039 pounds)
(Reporting by Ludwig Burger
Editing by David Holmes)

More News
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.

Read more
27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.

Read more
27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

Read more
27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the week.

Read more
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.